About this research notebook

How I choose what to read

I start from the question a page is trying to answer, not from a list of papers. For a code-named compound like ps r3, that usually means reading the neighbouring literature first: the named incretin peptides, the standard receptor binding assays, the analytical methods. The code itself is often nearly absent from the primary record, and pretending otherwise would make every page on this site dishonest.

I prioritise peer-reviewed primary literature, then regulatory documents, then university and government laboratory material. Catalogue text and vendor pages I read only to understand what is being claimed in the market, never as evidence for anything. Where a claim exists only in commercial copy, I record that fact rather than the claim.

How I check what I have read

Every factual statement in these notes goes through the same check: which paper, which lot, which assay, which organism or preparation. If a sentence cannot name its source, it gets rewritten as an explicit inference or deleted. My reviewer, Douglas Reyes, PhD, reads each page for pharmacological accuracy and for places where my chemistry framing drifts beyond what the data supports.

I also check my own older pages. When I reread something I wrote two years ago and cannot reconstruct the citation chain, I fix the page or pull it. A notebook that cannot be audited by its own author is not a notebook; it is a pile of assertions.

How and when I update these pages

I update when the record changes, not on a calendar. If a new primary paper characterises a compound I have written about, or a regulator publishes something relevant, the affected page gets revised and the note at the bottom changes date. Pages that have not changed are left alone; I do not stamp fresh dates on unchanged text, because that would make the dates meaningless.

Why the notebook accepts no advertising

This site runs no advertisements, no affiliate arrangements, and no sponsored placements of any kind. The field I am writing about is saturated with commercial incentives, and the moment a page about a code-named compound also carries a procurement pathway, every careful sentence around it becomes suspect. Keeping the notebook unfunded was the cheapest way to keep it credible.

Who writes and who reviews

I am Marion Kessler, MSc, an independent compiler of peptide chemistry literature with no institutional affiliation. I draft every page. Douglas Reyes, an independent pharmacology reviewer, reviews each one before it goes live. Neither of us speaks for any institution, and neither of us has any commercial relationship with any compound, supplier, or laboratory mentioned in these notes.